TY - JOUR
T1 - Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
AU - Degirolamo, Chiara
AU - Sabbà, Carlo
AU - Moschetta, Antonio
N1 - Funding Information:
The authors apologize to our distinguished colleagues whose work has not been cited owing to space limitations. The authors are indebted to Dr R. Le Donne for the artwork. The authors received research grants from the European Marie Curie Initial Training Network (NR-NET 606806), the Italian Association for Cancer Research (AIRC, IG 14732), the Italian Ministry of University and Education (Finanzia-menti per la Ricerca di Base IDEAS RBID08C9N7; PRIN 2010FHH32M-002), the Italian Ministry of Health (Young Researchers Grant GR-2010-2314703), Intercept Pharmaceuticals (San Diego CA), NGM BioPharmaceuticals (San Francisco CA) and University of Bari Aldo Moro (IDEA GRBA0802SJ-2008).
Publisher Copyright:
© 2016 Macmillan Publishers Limited. All rights reserved.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.
AB - The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.
UR - http://www.scopus.com/inward/record.url?scp=84955209323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955209323&partnerID=8YFLogxK
U2 - 10.1038/nrd.2015.9
DO - 10.1038/nrd.2015.9
M3 - Review article
C2 - 26567701
AN - SCOPUS:84955209323
SN - 1474-1776
VL - 15
SP - 51
EP - 69
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 1
ER -